natgillin/translations-raw huggingface dataset:
Due to their improved capability of inducing cartilage formation, the recombinant GDF-5 related proteins of the present invention are particularly suitable for use in the treatment of diseases, wherein the formation of cartilage is desired but the formation of bone is undesirable. 
Varijanta proteina prema patentnom zahtjevu 1 ili nukleinska kiselina prema patentnom zahtjevu 2, za uporabu u liječenju bolesti, gdje je formiranje hrskavice poželjno, ali je formiranje kosti nepoželjno.
wherein the oral sulfate solution is to be ingested at more than one time before the administration of the capsule endoscope, or wherein an osmotic laxative is also to be administered, and the osmotic laxative is to be administered before the administration of the oral sulfate solution and a capsule endoscope. 
Upotreba u skladu s patentnim zahtjevom 6, naznačena time što oralnu otopinu sulfata treba primijeniti uz kapsularni endoskop, ili gdje oralnu otopinu sulfata treba primijeniti prije primjene kapsularnog endoskopa, ili gdje oralnu otopina sulfata treba progutati više puta prije primjene kapsularnog endoskopa, ili gdje također treba primijeniti osmotski laksativ, gdje osmotski laksativ treba primijeniti prije primjene oralne otopine sulfata i kapsularnog endoskopa.
a rabbit or rabbit-derived antibody, optionally a rabbit monoclonal antibody or a humanized rabbit monoclonal antibody. 
(b) antitijelo kunića ili antitijelo koje potiče od kunića, opcionalno monoklonsko antitijelo kunića ili humanizirano monoklonsko antitijelo kunića.
decoding of the downlink control information that is mapped to one of the plurality of candidates included in the search space. 
Metoda prijema sukladno jednom od zahtjeva 1 ili 2, naznačena time da je prostor pretraživanja konfiguriran u podatkovnom predjelu podokvira silazne veze.
and Z is —(C1-C4)-alkyl. In a further embodiment a process according to the present invention is applicable for the preparation of the compounds of formula IV, 
Z je (C,-Cg)-alkil ili benzil. 11. Postupak dobivanja spojevi formule IV u skladu s patentnim zahtjevima 9 ili 10, naznačen time što se sastoji u a) reakciji spoja formule II
The use of claim 3, 4, 7, 8 or 10 or a compound for use according to claim 5, 6, 7, 9 or 10, wherein the central nervous system disorder is selected from mild cognitive impairment, age-associated memory impairment, pre-senile dementia, early onset Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, Alzheimer's disease, Lewy Body dementia, micro-infarct dementia, AIDS-related dementia, HIV-dementia, multiple cerebral infarcts, Parkinsonism, Parkinson's disease, Pick's disease, progressive supranuclear palsy, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, attention deficit disorder, attention deficit hyperactivity disorder, anxiety, depression, dyslexia, schizophrenia, cognitive dysfunction in schizophrenia, depression, obsessive-compulsive disorders, or Tourette's syndrome. 
Upotreba prema zahtjevu 3, 4, 7 8 ili 10 ili spoj za primjenu prema zahtjevu 5, 6, 7, 9 ili 10, gdje poremećaj središnjeg živčanog sustava je poremećaj izabran od blagog kognitivnog pogoršanja, pogoršanja pamćenja u vezi sa godinama, presenilne demencije, ranog početka Alzheimerove bolesti, senilne demencije, demencije Alzheimerovog tipa, Alzheimerove bolesti, demencije Levijevih tela, mikroinfarktne demencije, demencije u vezi sa AIDS-om, HIV-demencije, višestrukih cerebralnih infarkta, parkinsonizma, Parkinsonove bolesti, Pickove bolesti, progresivne supranuklearne paralize, Huntigtonove koreje, tardivne diskinezije, uznemirenosti, depresije, disleksije, shizofrenije, kognitivne disfunkcije kod shizofrenije, depresije, opsesivno-kompulsivnih poremećaja ili Touretovog sindroma.
A monoclonal antibody having the ability of binding to CLD18A2 and mediating killing of cells expressing CLD18A2, wherein the antibody binds to an epitope localized on the CLD18A2-loop1 or the CLD18A2-loopD3 and wherein killing is induced by binding of the antibody to CLD18A2 expressed by said cells, wherein said antibody comprises a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following (i) to (ix): 
Monoklonsko antitijelo koje ima sposobnost vezanja za CLD18A2 i posredovanja u ubijanju stanica koje eksprimiraju CLD18A2, pri čemu se antitijelo veže za epitop lokaliziran na CLD18A2-petlji1 ili CLD18A2-petljiD3 i pri čemu je ubijanje inducirano vezanjem antitijela za CLD18A2 eksprimiranog od strane navedenih stanica, pri čemu antitijelo posreduje u ubijanju stanica indukcijom lize posredovane preko citotoksičnosti ovisne od komplementa (CDC) i/ili lize posredovane preko stanične citotoksičnosti zavisne od antitijela (ADCC).
Compound (I) is useful as an agent for the prophylaxis or treatment of metabolic syndrome. 
(I) gdje R! je kao definiran u zahtjevu 1, ili njegova sol, za proizvodnju sredstva za profilaksu ili liječenje oboljenja u kojima je sadržana inzulinska rezistencija.
1 shows a diagrammatic longitudinal section of a chill chamber with a container according to the present invention therein; 
1 prikazuje shematski uzdužni presjek hladne komore sa spremnikom u skladu s predmetnim izumom;
More methanol (10 ml) was added and the solution was added dropwise to a solution of omeprazole (10 g, 0.029 m) in methanol (200 ml) and the mixture was then stirred for 30 min at room temperature. 
Dodano je više metanola (10 ml) i otopina je dodana ukapavanjem u otopinu omeprazola (10 g, 0,029 m) u metanolu) (200 ml) i smjesa je tada miješana 30 min na sobnoj temperaturi.
T is H, a linear or branched, substituted or unsubstituted C1-C10 alkyl, linear or branched, substituted or unsubstituted C2-C10 alkenyl, linear or branched, substituted or unsubstituted C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted aryl, or PEG, wherein the backbone of C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl optionally comprises one or more heteroatoms; and n is an integer of 0-5, 
T je H, linearni ili razgranati, supstituirani ili nesupstituirani C1-C10alkil, linearni ili razgranati, supstituirani ili nesupstituirani C2-C10alkenil, linearni ili razgranati, supstituirani ili nesupstituirani C2-C10alkinil, opcijski supstituirani ciklil, opcijski supstituirani aril, ili PEG, pri čemu kostur C1-C10alkila, C2-C10alkenila, C2-C10alkinila opcijski sadrži jedan ili više heteroatoma; i n je cijeli broj od 0-5, ili njegova sol, solvat ili ester.
at least one cooking chamber (2) in the form of a pot in which the coffee is cooked, 
barem jednu komoru za kuhanje (2) u obliku lonca u kojem se kuha kava,
While the degree of substitution of HIC adsorbents may be in the range of 10-50 µmoles/mL of matrix of C2-C8 aryl ligands, several hundred µmoles/mL of matrix of C4-C8 alkyl ligands are usually used for reverse phase chromatography adsorbents. 
Dok je stupanj zamijene apsorbenata u HIC-u u rasponu od 10-50 umola/mL u matriksu C2-C8 s arilnim ligandima, za apsorbente u kromatografiji obrnute faze iznosi nekoliko stotina umola/mL u matriksu C4-C8 s alkilnim ligandima.
Representative factors include the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, on whether an acute or chronic disease state is being treated is conducted or on whether further active compounds are administered in addition to the compounds of the Formula (I) and as part of a drug combination. 
Primjeri takvih faktora uključuju tip, dob, težinu, spol, dijetu i medicinsko stanje pacijenta kao i jačinu bolesti, put primjene, farmakološke uvjete poput aktivnosti, učinkovitosti, farmakokinetičkih i toksikoloških profila određenog primjenjenog spoja, te koristi li se sistem oslobađanja lijeka, radi li se o akutnom ili kroničnom statusu bolesti koja se tretira ili se provodi profilaksa te koristi li se još koji aktivni sastojak kao dodatak spojevima Formule (T) ili se radi o kombinaciji lijekova.
The compositions according to claim 4, 5 or 6 wherein the expandable beads/granules, of both type (a) and (b), consist of vinyl aromatic polymers and/or copolymers having an average molecular weight Mw ranging from 50,000 to 300,000. 
Smjese u skladu s patentnim zahtjevom 4, 5 ili 6, naznačene time što se ekspandibilna zrna/granule, oba tipa (a) i (b), sastoje od viniliranih aromatskih polimera i/ili kopolimera prosječne molekulske težine MW u rasponu od 50.000 do 300.000.
The optical navigation system of claim 1, at least one of the markers comprising a characteristic feature comprising any one or more of the group consisting of: the marker being of a particular shape; the marker comprising a barcode; and the marker being automatically identifiable by a machine vision system. 
Sustav za optičku navigaciju (10) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje jedna od oznaka (26) sadrži karakteristično obilježje, gdje je karakteristično obilježje bilo koje od ili više toga iz skupine koju čine: oznaka određenog oblika; oznaka koja sadrži barkod; te oznaka koju automatski prepoznaje sustav za strojno gledanje.
The pharmaceutical composition according to claim 16, wherein the antihistamine is fexofenadine, desloratadine, loratadine or citirizine, the leukotriene antagonist is montelukast or zafirulast, the beta agonist is albuterol, salbuterol or terbutaline, the PDE4 inhibitor is roflumilast or cilomilast, the TP antagonist is Ramatrobran, and the CrTh2 antagonist is Ramatrobran. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 16, naznačen time što antihistaminik je feksofenadin, desloratadin, loratadin ili cetirizin, leukotrienski antagonist je montelukast ili zafirlukast, B-agonist je albuterol, salbuterol ili terbutalin, inhibitor PDE4 je roflumilast ili cilomilast, antagonist TP je ramatroban, te antagonist CrTh2 je ramatroban.
a lipophilic flavouring agent that is solubilised by means of a water-miscible oil-based solvent; and/or 
lipofilno sredstvo za poboljšanje okusa koje je solubilizirano pomoću otapala na bazi ulja koje se miješa s vodom; i/ili
The method according to claim 12 for increasing milk protein content. 
Postupak prema zahtjevu 12 za povećanje udjela mliječnih bjelančevina.
A water treatment facility comprising: 
Postrojenje za obradu vode (1), naznačen time, da:
The hydrogenation is finished after 1 hour at RT, the catalyst filtered off and the filtrate evaporated at 30°: white solid. 
Hidriranje je završeno nakon jednog sata na RT, katalizator se ukloni filtriranjem 1 filtrat se evaporira na 30 "C: bijela krutina.
A compound of formula (I) or a physiologically acceptable solvate thereof as defined in claim 1 or claim 2, for use in veterinary or human medicine. 
Spoj formule (1), ili njegov fiziološki prihvatljiv solvat, u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u veterini ili mađicini.
The method according to claim 6, wherein the ionizing radiations are of about 2 KeV to 6000 KeV. 
Uporaba prema zahtjevu 8, gdje su ionizirajuća zračenja od oko 2 KeV do 6000 Kev.
Antibody according to claim 1 to 2, whereby the antibody consists of an antigen-binding region that binds specifically to one or more regions of the extracellular domain of PRLR from human, monkey and mouse, and whereby the amino acid sequences of the human PRLR are depicted by the amino acid sequences from position 1 to 210 of SEQ ID NO: 12 and human polymorphic variants of SEQ ID NO: 12, by the amino acid sequences from position 1 to 210 of the monkey PRLR according to SEQ ID NO: 11 and of the mouse PRLR according to SEQ ID NO: 13. 
Protutijelo ili njegovi fragmenti koji vežu antigen prema zahtjevu 1, naznačeno time da protutijelo ili njegovi fragmenti koji vežu antigen sadrže regiju koja veže antigen koja se specifično veže na jednu ili više regija izvanstanične domene prolaktin receptora (PRLR) iz čovjeka, majmuna i miša, te pri čemu su sekvence amino kiseline za ljudski PRLR prikazane sa sekvencom amino kiseline od položaja 1 do 210 iz SEQ ID NO: 12 i ljudske polimorfne varijante iz SEQ ID NO: 12, sa sekvencom amino kiseline od položaja 1 do 210 majmunskog PRLR u skladu sa SEQ ID NO: 11 i mišjeg PRLR u skladu sa SEQ ID NO: 13.
The nucleic acid according to Claim 8 which is DNA, cDNA, PNA, CNA, RNA or combinations thereof. 
Nukleinska kiselina sukladno Tvrdnji 4 koja je DNA, cDNA, PNA, CNA, RNA ili njihova kombinacija.
the pharmaceutical composition is in the form of a unit dosage comprising 0.0033 mg - 200 mg of said mature elastase protein; 
(iv) farmaceutski sastav je u obliku jedinične doze obuhvaćajući 0.0033 mg - 200 mg spomenute zrele protein elastaze;
0.51 Procedure Nebivolol hydrochloride 5.45 mg (2.41% w/w) was added to methanol with stirring (1% w/v drug solution in methanol). 
Nebivolol hidroklorid 5,45 mg (2,41 % w/w) dodan je u metanol uz miješanje (1 % w/v otopina lijeka u metanolu).
The resulting alcohol is oxidized to aldehyde (M) using any variety of methods, for example, Dess-Martin periodinane (i.e., 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one), Swern Oxidation, Corey oxidation with NCS or any other suitable method as described by Hudlicky, M. in Oxidations in Organic Chemistry, ACS Monograph 186 (1990). 
Rezultirajući alkohol se oksidira do aldehida (M) uporabom različitih postupaka, na primjer, Dess-Martin periodinana (t.j. 1,1,1-triacetoksi-1,1-dihidro-1,2-benziodoksol-3(1H)-spoj), Swem Oxidation, Corey Oxidation sa NCS ili bilo kojom drugom prikladnom metodom kao što to opisuje Hudlicky, M. u Oxidations in Organic Chemistry, ACS Monograph 186 (1990).
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
Compositions and methods for modulating complement factor B expression 
SASTAVI I POSTUPCI ZA MODULIRANJE EKSPRESIJE KOMPLEMENTA FAKTORA B
with the proviso that when X1 is an acidic amino acid, then X4 is a basic amino acid; and when X1 is a basic amino acid, then X4 is an acidic amino acid. 
uz uvjet kada je X1 kisela aminokiselina, tada je X4 bazna aminokiselina; i kada je X1 bazna aminokiselina, tada je X4 kisela aminokiselina.
fixing of at least one net (230) to the air inlet of the chiller, 
- pričvršćivanje najmanje jedne mreže (230) na ulazni otvor zraka hladnjaka,
Compounds of the formula I in which: 
Spojevi s formulom I naznačeni time da
Fig. 11 shows that while rapamycin induces nearly 80% platelet aggregation after 8 minutes, 42-O-(D-Fructosylcarbonyl)rapamycin does not exhibit a measurable effect on platelet aggregation in the same time. 
Slika 11 pokazuje da, dok rapamicin inducira gotovo 80% agregacije trombocita nakon 8 minuta, 42-O-(fruktozilkarbonil)rapamicin ne pokazuje mjerljiv učinak na agregaciju trombocita u istom vremenu.
SUMMARY OF THE INVENTION However, since in most cases of abuse it is still necessary to pulverise the dosage form comprising an active ingredient suitable for abuse, it was the object of the present invention to complicate or prevent the pulverisation preceding abuse of the dosage form comprising the agents conventionally available for potential abuse and accordingly to provide a dosage form for active ingredients with abuse potential which ensures the desired therapeutic effect when correctly administered, but from which the active ingredients cannot be converted into a form suitable for abuse simply by pulverisation. 
Budući da je u većini slučajeva za zlouporabu potrebno pulveriziranje oblika davanja koji sadrži tvari prikladne za zlouporabu, zadaća ovog izuma bila je da se pulveriziranje oblika davanja koje prethodi zlouporabi oteža, odnosno spriječi sredstvima koja uobičajeno stoje na raspolaganju potencijalnom zlorabitelju i time stavi na raspolaganje kruti oblik davanja djelatnih tvari s potencijalom za zlouporabu, koji kod propisane aplikacije jamči željeno terapeutsko djelovanje, iz kojeg se oblika međutim djelatne tvari ne mogu jednostavnim pulveriziranjem prevesti u oblik koji je prikladan za zlouporabu.
providing a population of lymphocytes or T-cells, obtained from a subject, and optionally enriching or isolating and propagating said population of lymphocytes or T-cells; 
osigurava populaciju limfocita ili T stanica, dobivenu iz subjekta, i opcijski obogaćivanje ili izoliranje i reprodukciju, spomenute populacije limfocita ili T stanica;
In an embodiment of the composition, the composition further comprises rasagiline base. 
Sastav prema patentnom zahtjevu 7, naznačen time, da nadalje sadrži rasagilinsku bazu.
After this time, the solution was cool to RT and diluted with ethyl acetate. 
Nakon ovog vremena otopina je ohlađena na sobnu temperaturu i razrijeđena sa etil acetatom.
A first aspect of the invention relates to a method for producing a beverage from an ingredient-containing capsule. 
Prvi aspekt ovog izuma odnosi se na postupak za pripremanje napitka iz čahure koja sadržava sastojak.
Number of animals with seizures 
Broj međunarodne objave:
wherein R1, R3, R4 and Z1 are as defined in formula (I), with a compound of formula (VII) 
(VI) pri čemu R', R*, R* i Z! su kako je definirano u zahtjevu 1, sa spojem sa formulom (VII)
The pharmaceutical composition according to claim 12, further comprising another active ingredient, advantageously chosen from among anticancer agents, in particular comprising cytotoxic anticancer agents such as navelbine, vinflunine, taxol, taxoter, 5-fluorouracil, methotrexate, doxorabicin, camptothecin, gemcitabin, etoposide, cis-platin or carmustin; and hormonal anticancer agents such as tamoxifen or medroxyprogesterone. 
Farmaceutski pripravak prema patentnom zahtjevu 12, naznačeno time da dalje sadrži drugi aktivni sastojak, pogodno odabran od antikancerogenih sredstava, posebice da sadrži citotoksična antikancerogena sredstva kao što je navelbin, vinflunin, taksol, taksoter, 5-fluoruracil, metotreksat, doksorabicin, kamptotecin, gemcitabin, etopozid, cis-platin ili karmustin; te hormonska antikancerogena sredstva kao što je tamoksifen ili medroksiprogesteron.
Process of any of the preceding claims characterized in that the melanins comprise polihydroxyindole, eumelanin, feomelanin, alomelanin, neuromelanin, humic acid, fulerens, graphite, polyindolequinones, acetylene black, pyrrole black, indole black, benzene black, thiophene black, aniline black, poliquinones in hydrated form sepiomelanins, dopa black, dopamine black, adrenalin black, catechol black, 4-amine catechol black, in simple linear chain, aliphatics or aromatics; or their precursors as phenoles, aminophenols, or diphenols, indole poliphenols, ciclodopa DHI Y DHICA1 quinones, semiquinones or hydroquinones, L-tyrosine, L-dopamine, morpholin, ortho benzoquinone, dimorpholin, porphirin black, pterin black, ommochrome black, free nitrogen precursors, any of the above listed with any size or particles from 1 angstrom to 3 or 4 cm. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da melanini obuhvaćaju polihidroksiindol, eumelanin, feomelanin, alomelanin, neuromelanin, humičnu kiselinu, fulerene, grafit, poliindolkvinone, tamni acetilen, tamni pirol, tamni indol, tamni benzen, tamni tiofen, tamni anilin, polikvinone u hidratiziranom obliku, sepiomelanin, tamni dop, tamni dopamin, tamni adrenalin, tamni katehol, tamni 4-amin-katehol; jednostavne ravne lance, alifatske ili aromatske; ili njihove prethodnike kao što su fenoli, aminofenoli ili difenoli, indol polifenoli, ciklodop-DHI Y _ DHICAI1-kvinoni, semikvinoni ili hidrokvinoni, L-tirozin, L-dopamin, morfolin, orto-benzokvinon, dimorfolin, tamni porfirin, tamni pterin, tamni omokrom, slobodni dušikovi prethodnici; bilo koji od gore navedenih s bilo kojom veličinom ili s česticama od 1 angstroma do 3 ili 4 em.
Chemicals) Total weight mg 
200 g Chemicals) Ukupna težina
The anti-FGFR3 antagonist antibody of claim 1, wherein the antibody comprises a heavy chain variable region comprising SEQ ID NO:132 and a light chain variable region comprising SEQ ID NO:133. 
Anti-FGFR3 antagonističko protutijelo iz patentnog zahtjeva 1, pri čemu protutijelo obuhvaća varijabilnu regiju teškog lanca koja sadrži SEQ ID NO:132 i varijabilnu regiju lakog lanca koja sadrži SEQ ID NQ:133.
is an optionally substituted aliphatic, aromatic, or heteroaromatic group; and 
R' je izborno supstituirana alifatična, aromatična ili heteroaromatična grupa; i
is either absent or represents Lys, R1 represents NH2, R2 represents the C-terminal group of the peptidic compound and is selected from OH and NH2, or a salt or solvate thereof. 
je ili odsutan ili predstavlja Lys, predstavlja NH2, predstavlja C-terminalnu skupinu peptidnog spoja i odabrana je od OH i NH2, ili njegova sol ili solvat, pri čemu spoj je agonist GLP-1 i GIP receptora.
The concentrated solution at 20-25° C. was treated with 1,1′-carbonyidiimidazole (21.46 g, 0.132 mol) and stirred at 20-25° C. for 1 hr then treated with water (290 mL) and stirred rapidly at 20-25° C. for 24 hr. 
Koncentriranu otopinu na 20-25 "C obradi se 1,1'-karbonildiimidazolom (21,46 g, 0,1 32 mol), miješa na 1 sat 20-25 "C, obradi vodom (290 ml), te brzo miješa 24 sata na 20-25 *C. Smjesu se ostavi da se
comprises live attenuated canine adenovirus type 2 (CAV2) and live attenuated canine parvovirus (CPV) or 
(b) sadrži živi atenuirani adenovirus pasa tipa 2 (CAV2) i živi atenuirani parvovirus pasa (CPV) ili
is carboxylic, phosphonic, or phosphoric, in its salt or acid form; 
Au je karboksilna, fosfonska, ili fosforna, u njezinom obliku soli ili obliku kiseline;
Fig. 15 shows an embodiment is which the sealing material is pressurized by the fluid pressure, and 
Slika 15 prikazuje ostvarenje u kojemu je materijal za brtvljenje pritisnut fluidom pod tlakom, 1
The labeling occurs at the attachment group A through the coupling of radionuclides, MRI contrast agents, fluorescent pigments or chemotherapeutic agent. 
Derivati peptida GLP-! u skladu s prethodnim patentnim zahtjevima, naznačeni time što obilježavanje je konjugiranje radionuklida, kontrastni medij za MRT, fluorescentno bojilo i/ili kemoterapeutik.
In a 50 mL flask, 1.00 g (4.02 mmol) of 2-acetylthioisosorbide 5-mononitrate (12) obtained according to WO 00/20420 was dissolved in 20 mL of methyl alcohol and 10 mL of a 10% methanol solution of potassium hydroxide were added. The reaction mixture was covered and stirred for 5 hours at room temperature. 
U tikvici od 50 mL 1,00 g (4,02 mmola) 2-acetiltioizosorbid 5-mononitrata (12) dobivenog prema WO 00/20420 se otopi u 20 mL metil alkohola i doda se 10 mL 10%-tne metanolne otopine kalijevog hidroksida, Reakcijsku smjesu se pokrije 1 miješa se 5 sati pri sobnoj temperaturi.
The pharmaceutical composition for use according to claim 18, wherein said dermatoses is selected from the group consisting of Bullous disorders, dermatitis, papulosquamous disorders, erythema, lichen sclerosus et atrophicus, craurosis vulvae, discoid lupus erythematosus, morphea, Pemphigus, pemphigoid, dermatitis herpetiformis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, contact dermatitis, psoriasis, erythema multiforme. 
Farmaceutski sastav u skladu s patentnim zahtjevom 12, pri čemu je navedena dermatoza odabrana iz grupe koja se sastoji od buloznih poremećaja, dermatitisa, papuloskvamoznih poremećaja, eritema, atrofične lichen skleroze, krauroze vulve, diskoidnog eritemskog lupusa, morfeje, pemfigusa, pemfigoida, herpetiformnog dermatitisa, atopičnog dermatitisa, alergijskog kontaktnog dermatitisa, kontaktnog dermatitisa, psorijaze, multiformnog eritema.